Passionflower

Passionflower potentiates anesthetic and CNS-depressant agents via GABAergic mechanisms. It may slow nervous system function and prolong recovery from anesthesia. The NCCIH explicitly notes that Passionflower might interact with anesthesia drugs used before and after surgery and recommends avoidance in the perioperative period.

Discontinue Passionflower at least 2 weeks before elective surgery. Inform the anesthetic team if recent Passionflower use. Monitor for prolonged anesthesia recovery. Resume use only after full recovery from anesthesia.

Passionflower extracts have demonstrated potentiation of pentobarbital-induced sleeping time in animal models, consistent with additive GABAergic activity. The chrysin flavonoid in Passionflower acts as a partial GABA-A benzodiazepine receptor agonist, augmenting barbiturate-induced CNS depression.

Avoid combining Passionflower with barbiturate medications. The combination may cause unexpectedly profound sedation and respiratory depression. Patients on phenobarbital for epilepsy should be especially cautious as excessive sedation could mask breakthrough seizures.

High-dose Passionflower extract has demonstrated QT interval prolongation in pharmacological studies, possibly due to effects on cardiac potassium channels (blocking repolarizing K+ currents similar to Class III antiarrhythmics). Co-administration with drugs known to prolong QT interval could produce additive QT effects and increase arrhythmia risk.

Avoid high-dose Passionflower in patients on QT-prolonging medications. Use is contraindicated in patients with cardiac arrhythmias or long QT syndrome. If low-dose use is unavoidable, obtain baseline ECG and monitor periodically.

Passionflower extracts elicit GABA currents in hippocampal neurons in vitro and exert partial agonistic activity at benzodiazepine receptors. This mechanism is additive with benzodiazepine-mediated GABA-A receptor potentiation, increasing CNS depression. A clinical case report described a patient on lorazepam with Valerian and Passionflower who experienced handshaking, dizziness, and muscular fatigue from additive GABA receptor activity.

Caution patients on benzodiazepines against concurrent Passionflower use without medical supervision. If combined, use lowest effective doses and monitor for excessive sedation. Warn about impaired driving and falls risk, particularly in elderly patients.

Passionflower contains harman alkaloids (harmane, harmaline) which have intrinsic MAO-inhibitory activity (predominantly MAO-A inhibition, similar to reversible MAOIs). Concurrent use with prescribed MAO inhibitors may produce additive serotonergic effects, increasing risk of hypertensive crisis or serotonin toxicity.

Avoid concurrent use of Passionflower with MAO inhibitors. The harman alkaloids specifically inhibit MAO-A, raising concerns about interactions with tyramine-containing foods and with prescribed MAOIs or RIMAs. Screen patients for MAOI use before recommending Passionflower.

Passionflower flavonoids (chrysin, apigenin, vitexin) act as positive allosteric modulators at GABA-A receptors, enhancing chloride ion conductance and CNS inhibition. Alcohol similarly potentiates GABA-A receptor activity. Co-administration produces additive CNS depression, sedation, psychomotor impairment, and increased aspiration risk.

Advise patients not to combine passionflower with alcohol. Concurrent use increases the risk of excessive sedation, impaired coordination, and respiratory depression. The EMA monograph for Passiflora incarnata herba explicitly notes that concomitant use with CNS depressants including alcohol is not recommended.

Passionflower constituents potentiate GABAergic and possibly opioidergic central nervous system inhibition. Opioids cause CNS and respiratory depression via mu-opioid receptor activation. Additive CNS depression from concurrent passionflower use could increase sedation, impair respiratory drive, and elevate the risk of opioid toxicity.

Caution is warranted when passionflower supplements are used alongside opioid analgesics. Patients on chronic opioid therapy or using opioids for acute pain management should be advised of the potential for additive sedation and respiratory depression. Disclose passionflower use to prescribers before any opioid prescription.

Passiflora incarnata extracts elicit GABA currents in hippocampal neurons in vitro and have demonstrated anticonvulsant effects in animal models. Additive pharmacodynamic activity with anticonvulsant medications may increase CNS sedation and potentially alter seizure threshold unpredictably. Some alkaloids in passionflower (harman-type) also inhibit MAO, potentially affecting neurotransmitter levels relevant to seizure control.

Exercise caution when patients use passionflower alongside anticonvulsant medications. Monitor for excessive sedation and any changes in seizure frequency or control. Patients with epilepsy should inform their neurologist of passionflower use. Do not substitute passionflower for prescribed anticonvulsants.

A randomised double-blind clinical trial evaluated the combination of Passiflora incarnata extract (60 drops/day) with clonidine (0.8 mg/day) in opioid withdrawal. The combination was significantly more effective than clonidine alone for managing withdrawal symptoms over 14 days, suggesting complementary CNS modulatory mechanisms. Passionflower may enhance clonidine sedative and autonomic stabilising effects.

The combination of passionflower with clonidine for opioid withdrawal management may be beneficial under medical supervision. However, monitor for additive hypotension and sedation. Do not combine without clinical oversight as additive central nervous system and cardiovascular depression could become hazardous in unmonitored settings.

Passionflower modulates serotonergic neurotransmission and contains harman alkaloids that exhibit weak MAO inhibitory properties. Combined use with SSRIs theoretically raises risk of serotonin syndrome, particularly at high doses of passionflower. The clinical significance is uncertain, but the pharmacological basis for the interaction is mechanistically plausible.

Caution is warranted when combining passionflower with SSRIs, particularly at higher doses. Counsel patients to report serotonin syndrome symptoms (agitation, confusion, tachycardia, hyperthermia, myoclonus, diaphoresis). The interaction risk at standard passionflower doses is considered low, but clinical vigilance is appropriate.